//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
Phase 2 Silevertinib Results in Non-Classical EGFR-Mutant NSCLC - Aakash Desai @adesaimd.bsky.social oncodaily.com/voices/aakas... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
18d
Aakash Desai: Phase 2 Silevertinib Results in Non-Classical EGFR-Mutant NSCLC / Aakash Desai, ASCO26, Black Diamond Therapeutics, cancer, Lung cancer, NSCLC,
oncodaily.com
Aakash Desai: Phase 2 Silevertinib Results in Non-Classical EGFR-Mutant NSCLC - OncoDaily
OncoDaily